Skip to main content

The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms

Abstract

Background

Serum ferritin levels are elevated in many malignancies. In this study, we showed the performance of serum ferritin in identifying malignant intraductal papillary mucinous neoplasms (IPMNs).

Methods

A total of 151 patients with pathologically confirmed IPMNs were enrolled. Serum tumor biomarker (carbohydrate antigen 19–9 (CA19–9) and carcinoembryonic antigen (CEA)) levels and serum ferritin levels were recorded. Lesion location, tumor size, diameter of the main pancreatic duct (MPD), mural nodule, and IPMN type, were collected from imaging examinations. IPMNs with high grade dysplasia and associated invasive carcinoma were considered malignant IPMNs.

Results

Serum ferritin levels in patients with malignant IPMNs were higher than those in patients with nonmalignant IPMNs (p <  0.05). Serum ferritin was an independent factor for the occurrence of malignant IPMNs (odds ratio (OR) = 1.18, 95% confidence interval (CI):1.01–1.39). A similar trend was found between high serum ferritin (> 149 ng/ml) and malignant IPMNs (OR = 5.64, 95% CI:1.78–17.92). The area under the curve (AUC) of serum ferritin was higher than that of CEA and CA19–9 in identifying malignant IPMNs (AUC = 0.67 vs. AUC = 0.58, 0.65). The combination of serum ferritin with IPMN type showed a similar performance to MPD diameter and the combination of serum CA19–9 with IPMN types in identifying malignant IPMNs (AUC = 0.78 vs. AUC = 0.79, 0.77) and invasive carcinoma (AUC = 0.77 vs. AUC = 0.79, 0.79).

Conclusions

Elevated serum ferritin is a factor associated with malignant IPMNs. Serum ferritin may be a useful marker for identifying malignancy in IPMNs.

Peer Review reports

Introduction

Intraductal papillary mucinous neoplasms (IPMNs) represent one type of cystic pancreatic neoplasms. The critical issue of IPMNs is their potential for malignant transformation. More than 40% of IPMNs are high-grade dysplasia or invasive carcinoma [1]. IPMNs are divided into three types based on the site of origin in the pancreatic ductal system: main-duct (MD) type, side-branch duct (BD) type, and mixed type (MT). MD-IPMNs are less common but have a higher risk of malignancy than BD-IPMNs [2]. A total of 38–87% of MD-IPMNs had malignant histological features in resected specimens [3, 4]. Surgical resection is usually performed for MD-IPMNs and MT-IPMNs due to their high risk of malignancy [5]. In 2012, the threshold diameter of the main pancreatic duct (MPD) for MD-IPMNs was set at 5.0 mm [6]. The need for surgical resection is not only based on MPD diameter but also based on “high-risk stigmata” and “worrisome features”, such as biliary obstruction and the presence of mural nodules. The early detection of the malignancy in IPMNs is important for treatment planning [7]. Whether other potential high-risk factors exist for identifying malignant IPMNs needs to be further explored.

Tumor biomarkers are usually elevated in malignant IPMNs [8, 9]. Hirono et al. showed that carcinoembryonic antigen (CEA) in the pancreatic juice was a biomarker of carcinomas in MD- and MT-IPMNs [8]. In addition, they also found that serum carbohydrate antigen 19–9 (CA19–9) was independently related to malignancy in MT-IPMNs [7]. Similar results were also reported in other studies [10,11,12,13,14]. Previous guidelines have not reported other potential serum biomarkers in the management of IPMNs.

Ferritin, consisting of 24 subunits, is ubiquitously expressed as an iron storage protein. The function of serum (extracellular) ferritin in human biology is not completely understood [14]. Elevated serum ferritin is found in chronic and acute inflammation [15]. Moreover, serum ferritin levels are elevated in many malignancies [15], including hepatocellular carcinoma, hematological malignancies, and lung and breast cancer. Several studies also showed that elevated serum ferritin can be found in patients with pancreatic duct adenocarcinoma [16, 17]. Serum ferritin is also related to short survival in patients with T-cell lymphoma [18], hepatocellular carcinoma [19, 20] and pancreatic cancer [21, 22]. Ferritin may also be associated with tumor progression [23]. However, the role of serum ferritin in IPMNs is poorly understood. Therefore, in this study, we showed the associations between serum ferritin and malignant IPMNs. In addition, we also showed the performance of serum ferritin in identifying the malignant IPMNs.

Materials and methods

Patients

A total of 151 patients with histologically proven IPMNs who underwent surgery during 2011–2020 were included. The patients collection protocol was described in an our previous study [24]. Briefly, the patients’ demographic information, medical history, clinical data, preoperative symptoms, serum CA19–9 level, serum CEA levels, and serum ferritin levels, and pathological data were collected from medical records. Serum ferritin, CA19–9 and CEA levels were determined within 1 week before operation. Diabetes mellitus (DM) was diagnosed based on plasma glucose levels or DM history. None of the patients received endoscopic ultrasound examinations. This study was approved by the Institutional Review Board of the the First Affiliated Hospital, Zhejiang University School of Medicine, and the requirement for informed consent was waived because of the retrospective design. The study adhered to the Declaration of Helsinki.

Imaging data

The following radiological data were collected from computed tomography (CT) or magnetic resonance imaging (MRI): lesion location (head-neck or body-tail), tumor size, MPD diameter, and mural nodule. If the lesion was too large, the location was evaluated based on the center of the cyst. If there were multiple lesions, the location of the main cyst was judged. IPMNs were classified into three types based on the degree of involvement of the pancreatic ductal system: MD-IPMNs, BD-IPMNs, and MT-IPMNs. MD-IPMNs were considered when there was segmental or diffuse involvement of the MPD; BD-IPMNs were considered when the lesions communicated with the MPD.

Histological examinations

The histological evaluation of each IPMN was based on the World Health Organization guidelines for IPMNs. The IPMNs were divided into three grades based on cytoarchitectural atypia: low-intermediate dysplasia, high-grade dysplasia, and invasive adenocarcinoma. Those IPMNs with high-grade dysplasia and associated invasive carcinoma were considered as malignant ones. Lymph node metastasis (yes vs. no) and peripancreatic extension (organ invasion and vascular invasion) were also evaluated.

Statistical analysis

The data was shown as as mean ± standard deviation (continuous data) or was shown as number (qualitative data). Clinicopathological variables including continuous data, such as patient’s age, tumor sizes, the serum levels of CEA, CA19–9, ferritin, MPD diameter were compared by Independent-sample T test or Mann-Whitney U-test. Qualitative data like sex, dysplasia level, tumor type (MD, BD and MT), tumor location (Head-neck vs Body and Tail), whether accompanied with chronic cholecystitis, pancreatitis, abdominal symptoms, diabetes, lymph node metastasis, peripancreatic extension, mural nodule were compared by Chi-square test or Fisher’s exact test. Univariable and multivariable logistic regression analyses were adopted to identify the associated factors for malignant IPMNs and invasive carcinomas. Additional adjustment with diabetes, pancreatitis and chronic cholecystitis were also performed because they may be related to serum ferritin levels. Receiver operating characteristic (ROC) curves were used to evaluate the performance of serum ferritin, MPD diameter, CA19–9, CEA in identifying malignant IPMNs and invasive carcinoma. P <  0.05 was considered as statistically significant.

Results

Patient clinicopathological features of malignant and non-malignant IPMNs

The clinical data is shown in Table 1. Overall, 47 patients (31.1%) had malignant IPMNs. Most nonmalignant IPMNs were BD-IPMNs; in contrast, malignant IPMNs was commonly seen among MD-IPMNs. The MPD diameter in malignant IPMNs was significantly larger than that in nonmalignant IPMNs (p <  0.05). Patients with malignant IPMNs had higher level of serum CA19–9 and serum ferritin than those with nonmalignant IPMNs. Peripancreatic extension and mural nodules were more commonly seen in malignant IPMNs (p <  0.01).

Table 1 Clinical data in malignant and nonmalignant IPMNs

Patient clinicopathological features of IPMN with and without invasive carcinoma

Next, we compared clinicopathological features between IPMN patients with and without invasive carcinoma (Table 2). Most of invasive carcinomas were MD type and mixed type (p <  0.01). In addition, invasive carcinomas had a larger pancreatic duct diameter than noninvasive carcinomas (p <  0.001). In addition, patients with invasive carcinoma had higher serum CEA and CA19–9 levels than patients without invasive carcinoma (p <  0.05). Abnormal CA19–9 levels were also more common in IPMN patients with invasive carcinoma than in those without invasive carcinoma. However, no significant difference was found in abnormal CEA levels between those with and without invasive carcinoma. Diabetes, lymph node metastasis, extrapancreatic expansion and the presence of mural nodules were more common in patients with invasive carcinoma (p <  0.05).

Table 2 Clinical data in IPMN with and without invasive carcinoma

The association between tumor grade and serum CEA, CA19–9, ferritin level

The serum CEA, CA19–9 and ferritin levels are shown in Fig. 1. Serum CEA, CA19–9 and ferritin levels were related to tumor malignancy (p <  0.05). IPMNs with malignant characteristics, including high-grade dysplasia and invasive carcinoma, always had higher serum CEA, CA19–9 and ferritin levels than non-malignant IPMNs (p <  0.05).

Fig. 1
figure1

The levels of serum carbohydrate antigen 19–9 (CA19–9) level, serum carcinoembryonic antigen (CEA) levels, and serum ferritin levels in intraductal papillary mucinous neoplasms (IPMNs). IPMNs were divided into low-moderate, high grade dysplasia and associated invasive carcinoma

ROC analysis

The performance of serum CEA, CA19–9, ferritin, pancreatic duct diameter and the combination of ferritin with tumor type in evaluating malignant IPMNs and carcinomas are shown in Fig. 2. When serum ferritin, CA19–9 or CEA was used alone, they had smaller areas under the curve (AUCs) for evaluating malignant IPMNs than MPD diameter (AUC = 0.78, 95% CI: 0.69–0.86) or the combination of ferritin with tumor type (AUC = 0.79, 95% CI: 0.71–0.87) (Fig. 2A). The AUC for identifying malignant IPMNs of serum ferritin was higher than that of CEA and CA19–9 (0.67 vs. 0.58, 0.65). The cutoff value for serum ferritin was 149 ng/ml, with a sensitivity of 89.4% and specificity of 55.4% in identifying malignant IPMNs.

Fig. 2
figure2

The receiver operating characteristic (ROC) curves of serum carbohydrate antigen 19–9 (CA19–9) level, serum carcinoembryonic antigen (CEA) levels, serum ferritin levels, main pancreatic duct (MPDF) diameter, and combination of serum ferritin with tumor type (ferritin + IPMN type) in predicting malignant intraductal papillary mucinous neoplasm (IPMN) (A) and invasive carcinoma (B)

Associated factors with malignant IPMNs

The associated factors for malignant IPMNs are listed in Table 3. Compared with MD-IPMNs, BD-IPMNs (OR = 0.07, 95% CI: 0.02–0.21) and MT-IPMNs (OR = 0.34, 95% CI: 0.13–0.94) had a lower risk for being malignant IPMNs. This association between BD-IPMNs and malignant IPMNs remained after adjusting for diabetes, pancreatitis and cholecystitis (OR = 0.06, 95% CI: 0.13–0.94). We also found that serum ferritin was an independent factor associated with malignant IPMNs (OR = 1.19, 95% CI: 1.04–1.35), and such trends remained after controlling for confounders, such as diabetes, pancreatitis and cholecystitis. A similar trend was found when serum ferritin was set as a categorical variable (threshold = 149 ng/ml) (OR = 5.64, 95% CI:1.78–17.92). However, age, sex, tumor size and tumor location had no significant association with malignant IPMNs. Serum ferritin levels were not associated with invasive carcinoma in multivariable logistic regression analysis (Table 4).

Table 3 Associated factors with malignant IPMNs
Table 4 Associated factors with invasive carcinoma

Discussion

IPMNs are one type of potentially malignant cystic lesion of the pancreas. The identification of malignancy is still a challenge even though several guidelines have shown ““high-risk stigmata“ and “worrisome features” [25]. It is of great importance to determine the risk factors of malignant IPMNs or carcinomas. Our study demonstrated that serum ferritin levels in patients with malignant IPMNs were significantly higher than those in patients with nonmalignant IPMNs. Multivariate logistic analysis also showed that serum ferritin level was an independent factor associated with malignant IPMNs. ROC analysis showed that serum ferritin level had a similar predictive performance to Ca19–9 in identifying malignant IPMNs. Thus, serum ferritin may have potential in predicting malignant IPMNs.

Previous studies have shown that several morphologic features of IPMNs and serum tumor biomarkers were associated with malignant IPMNs and invasive carcinoma [13, 15, 26]. MPD and mural nodules (enhancing solid component) were the two of main high risk stigmata. Our data also showed that MPD diameter and mural nodules were associated with invasive IPMNs which was in accordance with those previous findings. Recently, other possible factors that may be associated with malignant IPMNs have also been reported. Pergolini et al. [27]. pointed out that patients with IPMNs have a higher risk of high-grade dysplasia or invasive cancer when accompanied by diabetes or weight loss. Simpson et al. [28] found that combined pancreatic fluid interleukin-1β with pancreatic fluid prostaglandin E2 and serum CA19–9 could help discriminate high-grade dysplasia/invasive IPMNs from low/moderate-risk IPMNs. Elevated serum ferritin levels can occur in many malignancies [15]. However, few studies have shown the relationship between serum ferritin and malignant IPMNs.

Serum ferritin levels have been widely used as a tumor biomarker for clinical diagnosis and prognosis evaluation [15]. Ferritin may be used as a marker in renal cell carcinoma [29]. Orlandi et al. [30] showed that ferritin light chain had a good capacity for predicting malignant breast lesions (AUC = 0.86). Gao et al. [31] found that the combination of serum ferritin with four other tumor biomarkers had improved sensitivity for diagnosing colorectal cancer compared with CEA alone. Ferritin light chain (FTL) was an independent prognostic marker in patients with node-negative breast cancer tumors (HR:1.30; 95% CI:1.10–1.50) [32]. The possible role of serum ferritin in pancreatic cancer has also been investigated. Kalousová et al. found that elevated serum levels of ferritin indicated poor prognosis in the patients with pancreatic cancer [16]. Alkhateeb et al. also showed a similar result [33]. Pancreatic cancer patients who showed normal serum ferritin levels after chemoradiotherapy had a longer median progression-free survival than patients whose serum ferritin levels were not restored [22]. To our knowledge, no study has shown an association between serum ferritin levels and malignant IPMNs or invasive carcinoma. Our data indicated that serum ferritin levels were associated with malignant IPMNs. ROC analysis showed that the predictive performance of serum ferritin was similar to that of CA19–9, and higher than that of CEA. Elevated CA19–9 has been adopted as a “worrisome feature”. Serum ferritin may be another such feature. Our study is a primary exploration. Further explorations are required.

How ferritin affects the occurrence of malignancy in IPMNs is not clarified. Some studies have shown that the mechanism of tumor transformation and progression induced by ferritin. Ferritin is abundant in circulation and differently overexpressed in various malignant tumor tissues. A study reported that extracellular ferritin might exert immunosuppressive effects on myeloid cells and lymphocytes by modulating iron availability and that H-ferritin (known as heavy chain ferritin, a subunit of ferritin) had suppressive effects on myelopoiesis [15], which led to an immunosuppression in cancer patients. Coffman et al. [34] found that ferritin could promote assembly of tumor endothelial cells, promote angiogenesis during tumor growth and enhance the migration by antagonizing the antiangiogenic effects of HKa (cleaved high molecular weight kininogen). Tumor-associated macrophages (TAMs) in the breast tumor stroma can secrete ferritin which leads to the proliferation of epithelial breast cancer cells) [14]. Thus, regulating ferritin downregulation in TAMs may reduce their ability to maintain iron stores, which can result in tumor cell death. Conklin et al. [35] pointed out that ferritin might decrease the efficacy of chemotherapeutic drugs because of its antioxidant nature. The inhibition of H-ferritin in ferritin-rich glioma cells could sensitize cancer cells to the chemotherapeutic agents [36]. High ferritin expression enhanced progression and increased resistance to oxidative stress in metastatic melanoma [22, 37]. It is not clear which pathways are involved in the occurrence of malignancy in IPMNs. Further in vivo or in vitro studies are needed to show the biological role of ferritin in IPMNs.

Cytological findings are also an important high-risk stigmata in several guidelines. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has been a routine practice to collecting samples for cytology and cystic fluid analysis [38]. However, the accuracy rate and role of EUS-FNA in the identification of malignancy has not been proven [38]. A recent meta-analysis showed that the accuracy rate, sensitivity, and specificity of EUS-guided through-the-needle biopsy (EUS-TTNB) were 78.8, 82.2, and 96.8%, respectively [38]. The diagnostic yield of EUS-TTNB may be superior to that of EUS-FNA [38, 39]. The pooled concordance of EUS-TTNB with the histological grade of mucinous cysts was 75.6% [39]. The combination of EUS-TTNB and serum ferritin for identifying malignant IPMNs may be worthy of further study.

There are several limitations in our study. First, the number of BD-IPMNs was relatively small. Second, our study was a single-institution study which may cause selection bias, and a multicenter study should be performed to confirm our findings. Third, cyst fluid tumor marker levels [40, 41] and nonetumor biomarkers, such as microRNA and DNA [41, 42], are also useful for the identification of malignant IPMNs. However, we did not determine the ferritin level in cystic fluid or tumor tissues. Fourth, we did not perform a longitudinal study to show the associations between baseline serum ferritin and occurrence of malignant IPMNs. Fourth, some IPMN patients who did not undergo surgical resection were not included in our analysis, such as those patients undergoing surveillance and those who lost the chance to undergo surgery. The loss of these populations may affect the results. However, approximately 40% of our population that underwent surgery did not have “high-risk stigmata” or “worrisome features”. These subjects were comparable to the patients who underwent surveillance. Therefore, our results may also be useful for identifying malignancy in general population with IPMNs. However, further studies are required. Finally, as a retrospective study, we did not evaluate the association between serum ferritin and survival or recurrence after surgery and a prospective study is necessary in the future.

In conclusion, our study reports that elevated serum ferritin is associated with the presence of malignant IPMNs. Moreover, serum ferritin is also associated with invasive carcinoma in MPD-involved IPMNs. Serum ferritin may be a potential biomarker for identifying malignant IPMNs, especially for MPD-involved IPMNs. Multicenter studies and longitudinal studies are required to show the role of serum ferritin in the occurrence of malignant IPMNs.

Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Abbreviations

AUC:

Area under the curve

BD:

Branch duct

CA19–9:

Carbohydrate antigen 19–9 (CA19–9)

CEA:

Serum carcinoembryonic antigen

CT:

Computed tomography

DM:

Diabetes mellitus

EUS-FNA:

Endoscopic ultrasound-guided fine-needle aspiration

EUS-TTNB:

EUS-guided through-the-needle biopsy

FTL:

Ferritin light chain

IPMN:

INTRADUCTAL papillary mucinous neoplasms

MD:

Main duct

MPD:

Main pancreatic duct

MRI:

Magnetic resonance imaging

OR:

Odds ratio

ROC:

Receiver operating characteristic

TAMs:

tumor-associated macrophages

References

  1. 1.

    Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):824–48.

    Article  Google Scholar 

  2. 2.

    Elta GH, Enestvedt BK, Sauer BG, Lennon AM. ACG clinical guideline: diagnosis and Management of Pancreatic Cysts. Am J Gastroenterol. 2018;113(4):464–79.

    Article  Google Scholar 

  3. 3.

    Stark A, Donahue TR, Reber HA, Hines OJ. Pancreatic cyst disease: a review. JAMA. 2016;315(17):1882–93.

    CAS  Article  Google Scholar 

  4. 4.

    Marchegiani G, Mino-Kenudson M, Sahora K, Morales-Oyarvide V, Thayer S, Ferrone C, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015;261(5):976–83.

    Article  Google Scholar 

  5. 5.

    Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K. International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6(1–2):17–32.

  6. 6.

    Roch AM, Ceppa EP, Al-Haddad MA, DeWitt JM, House MG, Zyromski NJ, et al. The natural history of Main duct–involved, mixed-type Intraductal papillary mucinous neoplasm. Ann Surg. 2014;260(4):680–8.

    Article  Google Scholar 

  7. 7.

    Hirono S, Kawai M, Okada KI, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Yanagisawa A, Yamaue H. Factors associated with invasive Intraductal papillary mucinous carcinoma of the pancreas. JAMA Surg 2017;152(3):e165054.

  8. 8.

    Moris D, Damaskos C, Spartalis E, Papalampros A, Vernadakis S, Dimitroulis D, et al. Updates and critical evaluation on novel biomarkers for the malignant progression of Intraductal papillary mucinous neoplasms of the pancreas. Anticancer Res. 2017;37(5):2185–94.

    CAS  Article  Google Scholar 

  9. 9.

    Ciprani D, Morales-Oyarvide V, Qadan M, Hank T, Weniger M, Harrison JM, et al. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020;20(4):729–35.

    CAS  Article  Google Scholar 

  10. 10.

    Kim JR, Jang JY, Kang MJ, Park T, Lee SY, Jung W, et al. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas. J Hepatobiliary Pancreat Sci. 2015;22(9):699–707.

    Article  Google Scholar 

  11. 11.

    Jang JY, Park T, Lee S, Kim Y, Lee SY, Kim SW, et al. Proposed nomogram predicting the individual risk of malignancy in the patients with branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017;266(6):1062–8.

    Article  Google Scholar 

  12. 12.

    Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Werner J. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98(1):104–10.

    CAS  Article  Google Scholar 

  13. 13.

    Mimura T, Masuda A, Matsumoto I, Shiomi H, Yoshida S, Sugimoto M, et al. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol. 2010;44(9):e224–9.

    Article  Google Scholar 

  14. 14.

    Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–54.

    CAS  PubMed  Google Scholar 

  15. 15.

    Kalousová M, Krechler T, Jáchymová M, Kuběna AA, Zák A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 2012;33(5):1695–700.

    Article  Google Scholar 

  16. 16.

    Nitti D, Fabris C, Del Favero G, Farini R, Grassi F, Farini A, et al. Serum ferritin in pancreatic disease. An accurate test of malignancy? Digestion. 1982;25(4):258–62.

    CAS  Article  Google Scholar 

  17. 17.

    Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol. 2017;39(1):112–7.

    CAS  Article  Google Scholar 

  18. 18.

    Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(11):1905–10.

    CAS  Article  Google Scholar 

  19. 19.

    Wu SJ, Zhang ZZ, Cheng NS, Xiong XZ, Yang L. Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. Surg Oncol. 2019;29:159–67.

    Article  Google Scholar 

  20. 20.

    Alkhateeb A, Zubritsky L, Kinsman B, Leitzel K, Campbell-Baird C, Ali SM, et al. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease. J Gastrointest Cancer. 2014;45(2):161–7.

    CAS  Article  Google Scholar 

  21. 21.

    Wang SL, Cao S, Wu R, Chi F, Tang MY, Jin XY, et al. Serum ferritin predicted prognosis in patients with locally advanced pancreatic cancer. Future Oncol. 2015;11(21):2905–10.

    CAS  Article  Google Scholar 

  22. 22.

    Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, Santini D, et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res. 2005;11(9):3175–83.

    CAS  Article  Google Scholar 

  23. 23.

    Heckler M, Brieger L, Heger U, Pausch T, Tjaden C, Kaiser J, et al. Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas. BJS Open. 2018;2(1):13–24.

    CAS  Article  Google Scholar 

  24. 24.

    Wang C, Lin T, Wang X, Yu Z, ZhugeX, Cui W, Wang M , Wang Z , C Guo, Chen X. Low high-density lipoprotein cholesterol levels are associated with malignant intraductal papillary mucinous neoplasms: A multicenter study. Lipids in Health and Disease. 2021. https://doi.org/10.1186/s12944-021-01523-8

  25. 25.

    Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.

    Article  Google Scholar 

  26. 26.

    Shimizu Y, Hijioka S, Hirono S, Kin T, Ohtsuka T, Kanno A, et al. New model for predicting malignancy in patients with Intraductal papillary mucinous neoplasm. Ann Surg. 2020;272(1):155–62.

    Article  Google Scholar 

  27. 27.

    Pergolini I, Jäger C, Safak O, Göß R, Novotny A, Ceyhan GO, et al. Diabetes and weight loss are associated with malignancies in patients with Intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol. 2021;19(1):171–9.

    Article  Google Scholar 

  28. 28.

    Simpson RE, Yip-Schneider MT, Flick KF, Wu H, Colgate CL, Schmidt CM. Pancreatic fluid interleukin-1beta complements prostaglandin E2 and serum carbohydrate antigen 19-9 in prediction of Intraductal papillary mucinous neoplasm dysplasia. Pancreas. 2019;48(8):1026–31.

    CAS  Article  Google Scholar 

  29. 29.

    Kirkali Z, Esen AA, Kirkali G, Güner G. Ferritin. A tumor marker expressed by renal cell carcinoma. Eur Urol. 1995;28(2):131–4.

    CAS  Article  Google Scholar 

  30. 30.

    Orlandi R, De Bortoli M, Ciniselli CM, Vaghi E, Caccia D, Garrisi V, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol. 2014;25(2):352–7.

    CAS  Article  Google Scholar 

  31. 31.

    Gao Y, Wang J, Zhou Y, Sheng S, Qian SY, Huo X. Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep. 2018;8(1):2732.

    Article  Google Scholar 

  32. 32.

    Jézéquel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guérin-Charbonnel C, et al. Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int J Cancer. 2012;131(2):426–37.

    Article  Google Scholar 

  33. 33.

    Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is primarily localized within tumor-associated macrophages. Breast Cancer Res Treat. 2013;137(3):733–44.

    CAS  Article  Google Scholar 

  34. 34.

    Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A. 2009;106(2):570–5.

    CAS  Article  Google Scholar 

  35. 35.

    Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37(1):1–18.

    CAS  Article  Google Scholar 

  36. 36.

    Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N, Connor JR. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Cancer Res. 2011;71(6):2240–9.

    CAS  Article  Google Scholar 

  37. 37.

    Di Sanzo M, Gaspari M, Misaggi R, Romeo F, Falbo L, De Marco C, et al. H ferritin gene silencing in a human metastatic melanoma cell line: a proteomic analysis. J Proteome Res. 2011;10(12):5444–53.

    Article  Google Scholar 

  38. 38.

    Facciorusso A, Del Prete V, Antonino M, Buccino VR, Wani S. Diagnostic yield of EUS-guided through-the-needle biopsy in pancreatic cysts: a meta-analysis. Gastrointest Endosc 2020;92(1):1–8.e3.

  39. 39.

    Westerveld DR, Ponniah SA, Draganov PV, Yang D. Diagnostic yield of EUS-guided through-the-needle microforceps biopsy versus EUS-FNA of pancreatic cystic lesions: a systematic review and meta-analysis. Endosc Int Open. 2020;8(5):E656–67.

    Article  Google Scholar 

  40. 40.

    Sultana A, Jackson R, Tim G, Bostock E, Psarelli EE, Cox TF, et al. What is the best way to identify malignant transformation within pancreatic IPMN: a systematic review and Meta-analyses. Clin Transl Gastroenterol. 2015;6(12):e130.

    CAS  Article  Google Scholar 

  41. 41.

    Rockacy M, Khalid A. Update on pancreatic cyst fluid analysis. Ann Gastroenterol. 2013;26(2):122–7.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Matthaei H, Wylie D, Lloyd MB, Dal Molin M, Kemppainen J, Mayo SC, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012;18(17):4713–24.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

This study was funded by Zhejiang Provincial Natural Science Foundation (LY18H180004) and Zhejiang Medical Science and Technology Project (2017KY331).

Author information

Affiliations

Authors

Contributions

X. Zhuge: Data curation, Formal analysis, Writing – original draft, Writing - review & editing. H. Zhou: Data curation, Formal analysis, Writing – original draft, Writing - review & editing. L. Chen: Data curation, Formal analysis, Writing - review & editing; Z.Wang: Formal analysis, Writing- review & editing. X. Chen: Conceptualization, Methodology, Data curation, Visualization, Writing - review & editing. C. Guo: Conceptualization, Methodology, Writing - review & editing. All authors have read and approved the manuscript.

Corresponding authors

Correspondence to Xiao Chen or Chuangen Guo.

Ethics declarations

Consent to publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Ethics Board of the First Affiliated Hospital, Zhejiang University School of Medicine. Declaration of Helsinki was followed during the study.

Competing interests

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhuge, X., Zhou, H., Chen, L. et al. The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms. BMC Cancer 21, 1253 (2021). https://doi.org/10.1186/s12885-021-08986-z

Download citation

Keywords

  • Intraductal papillary mucinous neoplasms
  • Ferritin
  • Malignancy
  • Invasive carcinoma